Dr Raj Chovatiya Explains Oral JAK Inhibitor Monitoring Protocols for AD Treatment

EP: 1.Ruxolitinib Cream Improves AD Across Body Regions, Shows Efficacy, Safety in Black Patients

EP: 2.Upcoming Generics Provide New Considerations and Opportunities for Savings

EP: 3.Managed Care Has a Key Role in Biosimilar Adoption, Says Cardinal's Oskouei

EP: 4.Dr John Harris: There Are a Lot of Reasons to Talk About Vitiligo at This Year’s AAD Meeting

EP: 5.Dermatologists’ Focus to Delve Below the Skin at Annual Conference

EP: 6.Experts Herald “Year of the JAK Inhibitor” in Dermatology

EP: 7.Dr Monica Li Highlights Advances in Microneedling

EP: 8.Dr Eva Parker: Climate Change Has Been Impacting Skin Diseases for Years

EP: 9.Dermatology Data Can Direct Policy Priorities, but Gaps Reflect Inequities of Care

EP: 10.Dr John Harris Outlines the Outcomes of Stopping Treatment With Ruxolitinib Cream for Vitiligo

EP: 11.Late-Breaking Abstracts Demonstrate Value of Persistence With Ruxolitinib Cream for Vitiligo

EP: 12.Examining Dermatological Care for Transgender Patients

EP: 13.How Our Understanding of Inflammatory Skin Disease Has Evolved From the 4 Humors to Targeted Therapies

EP: 14.Dr Haley Naik Discusses Using Biologics and the Drug Pipeline for Hidradenitis Suppurativa

EP: 15.Drs Dellavalle and Rodriguez Discuss Disparities in Prescription Patterns for Atopic Dermatitis

EP: 16.Posters Show Success of Ruxolitinib Cream in Alleviating Facial Vitiligo Symptoms, Reducing Noticeability

EP: 17.Investigators Highlight Disparities Evident in Skin Disease Care, Data Collection

EP: 18.Studies Presented at AAD Examine Safety and Satisfaction of Tildrakizumab for Psoriasis

EP: 19.Patients With AD Have More Options With Biologics, JAK Inhibitors, Says Dr Emma Guttman-Yassky

EP: 20.Dermatologists Looking to the Future Will Need to Be Their Own Advocates, Panel Says

EP: 21.Teledermatology Can Increase Access for Patients With High-Risk Melanoma: Erik Jaklitsch

EP: 22.Dr Sancy Leachman: Melanoma Metastasizes Quickly, Needs to Be Caught Early

EP: 23.Panel Discusses Treating Acne, Psoriasis in Dermatology Patients

EP: 24.New and Upcoming Treatment for Vitiligo, Atopic Dermatitis

EP: 25.Long-Term Safety of Dupilumab in Adults With Moderate to Severe Atopic Dermatitis

EP: 26.Evaluating Label Warnings, Switching Rates in Patients With Psoriasis Initiating New Treatment

EP: 27.ICYMI: Highlights From RAD 2023

EP: 28.AAD 2024 to Feature Topics Including JAK Inhibitors, Biologics

EP: 29.Dr Amy Paller Previews the 2024 AAD Annual Conference

EP: 30.Ruxolitinib Reduces Extent, Severity of AD and Need for Other Treatments

EP: 31.Dr Raj Chovatiya Outlines Who Is a Good Candidate for Oral JAK Inhibitors

EP: 32.Atopic Dermatitis in Adults: Challenges and Treatment Strategies

EP: 33.Dr Robert Sidbury: Understanding What Makes a Dermatology Practice Successful

EP: 34.Dr Monica Li Discusses Tailoring Microneedling Treatments to Meet Each Patient's Need

EP: 35.Skin Tone Bias Persists in Google Searches for Vitiligo

EP: 36.Management of HS Requires Both Coordination, Communication Between Patients and Providers

EP: 37.Dr Jonathan Silverberg Discusses Findings on the Safety, Efficacy of Nemolizumab at 48 Weeks

EP: 38.Biologic, Topical Therapies Both Effective in Treating AD in Skin of Color

EP: 39.Late-Breaking Abstracts Highlight Promising Therapies in AD, Hidradenitis Suppurativa

EP: 40.Dr Jeff Stark: Pain Reduction With Bimekizumab-bkzx in Patients With HS

EP: 41.Dr Martin Dahl Discusses the Pathophysiology of AD and Benefits of ANB032

EP: 42.New Study Links Social Factors to Hidradenitis Suppurativa Severity

EP: 43.Dr Laura Ferris Discusses Safety, Efficacy of JNJ-2113 in Patients With Plaque Psoriasis

EP: 44.Dr Shawn Kwatra Shares Efficacy, Safety Data of Nemolizumab in Patients With PN

EP: 45.Brodalumab Is Effective, Safe in Patients With Moderate to Severe Psoriasis

EP: 46.Patients With Vitiligo Suffer Heightened Stigma, Mental Health Risks

EP: 47.Racial Variations in Cardiovascular Outcomes Found in Hidradenitis Suppurativa Study

EP: 48.Autoimmune Comorbidities Prevalent in Patients With Vitiligo

EP: 49.Skin Cancer Incidence Highest Among Rural, SOC Individuals

EP: 50.Dupilumab Considered Safe, Effective Treatment for Adolescent, Adult Patients With AD

EP: 51.Gaps in Skincare Knowledge, Sun Protection Practice Exist Among Patients With Lupus

EP: 52.Dr Raj Chovatiya Provides Evidence Supporting Oral JAK Inhibitor Use to Treat AD

EP: 53.Undertreatment, Biologic Access Gaps Identified in Psoriasis Treatment

Now Viewing

EP: 54.Dr Raj Chovatiya Explains Oral JAK Inhibitor Monitoring Protocols for AD Treatment

EP: 55.Dr Monica Li Lists Microneedling Considerations, Precautions

EP: 56.Dr Jonathan Silverberg Describes AD Diagnosis, Treatment in Children vs Adults

EP: 57.Dr Lawrence Eichenfield Discusses Positive Results of Roflumilast Cream 0.05% in Pediatric Patients With AD

EP: 58.Dr Robert Sidbury on Implementing Value-Based Care Initiatives in a Pediatric Dermatology Practice

EP: 59.Dr Monica Li Explains Efficacy, Safety Differences Between Different Microneedling Techniques

EP: 60.Dr Lawrence Eichenfield Hopeful for New Pediatric AD Treatment Option

EP: 61.Dr Martina Porter Shares Findings on Ruxolitinib Cream in Patients With HS

EP: 62.Dr Martin Dahl Summarizes Findings, Limitations of Study Analyzing ANB032 Use in Patients With AD

Raj Chovatiya, MD, PhD, associate professor at the Rosalind Franklin University of Medicine and Science, described monitoring protocols for clinicians when using oral Janus kinase (JAK) inhibitors to treat patients with atopic dermatitis (AD).

Chovatiya is also the founder and director of the Center for Medical Dermatology and Immunology Research in Chicago, Illinois.

Transcript

Given the systemic nature of oral JAK inhibitors, what are the considerations and monitoring protocols that clinicians should follow when prescribing these medications for patients with AD, particularly in terms of managing adverse effects and assessing treatment response?

I like to tell individuals that I chat with about oral JAK inhibitors, don't be scared or frightened or even a little nervous about the fact that maybe there's a couple more points that you're going to talk about with your patients. If anything, that just makes you a better and more well-informed clinician to really be thinking about what is going to be the best therapy for that patient in front of you.

When it comes to starting and initiation, on label, both JAK inhibitors abrocitinib and upadacitinib recommend starting at the lowest dose; that would be 100 milligrams of abrocitinib, 15 milligrams for upadacitinib. Then, based on your clinical assessment, if someone was not getting an optimal response—and that could include you feeling like they're not getting fast enough resolution of their itch or lesions—you can bump them up to the higher dose.

Now, in terms of monitoring, there's a few labs that we think about monitoring at baseline. Generally, some of the normal infectious stuff we do, just like other systemic therapies, hepatitis B, hepatitis C, TB [tuberculosis] testing.

Then, some of the other additional labs. In the case of abrocitinib, you're going to be thinking about doing a CBC [complete blood count], and, let's say, lipid profile at baseline, and then about 4 weeks after. Then, if you're going to be making a dosing change, another 4 weeks after that.

In the case of upadacitinib, slightly different labs. You're going to be doing the same CBC and lipid panel, but also you're going to be adding on liver function tests. Typically, you're going to be taking a look at baseline and then as clinically indicated for most of these. Twelve weeks is kind of a good number that I like just because that's when you're going to be checking lipids anyway.

Beyond that, lab monitoring is a snap because it really is up to you and the patient about when you're going to check these things. The nice thing about the data we've gotten so far is that lab abnormalities seem to be pretty rare. If they really were to pop up, it's usually within the first few months of therapy itself when you actually aren't checking labs. Now, thinking about some of the other issues that we would note on the label, if somebody was to develop an infection while on therapy, or had one at baseline, you want to get it treated and pause therapy.

In terms of the other more rare stuff that I just talked about from the boxed warning, whether it be related to heart issues, blood clotting issues, cancer, and things like that. Obviously, at baseline, if this is something you're dealing with, you want to try to get a good handle on that before thinking about therapy. If this was something that developed while you were on therapy itself, you'd want to pause, make sure you assess, and get that under control before considering restarting therapy again.